Evolva announces new CEO

11-Jul-2018 - Evolva announces that as part of entering the next phase of its evolution, the current Evolva CEO Simon Waddington steps down as CEO with immediate effect. Until he will leave the company towards the end of 2018, he will support the new CEO in completing work on Evolva’s technology base. This ...

Neil Goldsmith stepping down as CEO and Board member of Evolva

10-Jul-2017 - Evolva announces the departure of CEO Neil Goldsmith and his succession by the current Chief Operating Officer (COO), Simon Waddington. Since co-founding Evolva, Neil Goldsmith has been instrumental in Evolva’s development over the last thirteen years, moving the company from a pharmaceutical ...

Scott Fabro to Join Evolva as Chief Commercial Officer

12-Jun-2017 - Evolva announces that Scott Fabro will join Evolva early July and shortly thereafter take over as Chief Commercial Officer, succeeding Luc Gruner. Scott has broad executive experience in various marketing functions in the food industry including ACH Foods, Kerry and Cargill. Most recently he has ...

Evolva enters partnership on active pharmaceutical ingredients

Partner to fully fund development of new production routes for a family of APIs

18-Aug-2016 - Evolva has entered into an agreement with a private US biotech venture to develop new production routes for a family of existing active pharmaceutical ingredients (“API”). Evolva will be responsible for the development of the production routes, whilst the partner will be responsible for the ...

Evolva to co-develop next-generation materials with US Navy

13-Apr-2016 - Evolva announced that it has completed a Limited Purpose Cooperative Research and Development Agreement (CRADA) to support the joint development of novel advanced materials with the US Navy. The focus of the efforts supported by this CRADA relate to the development, validation and potential ...

Evolva scientists co-author paper on diterpene biosynthesis of economically relevant commercial targets

14-Mar-2016 - Plant-derived diterpenoids are used extensively in food ingredients, pharmaceuticals, and fragrances. Conventional wisdom holds that they are too rare and structurally complex to be commercially useful. However, by mimicking the modularity of diterpene biosynthesis in plants, the authors ...

Evolva and Valent BioSciences to co-develop agricultural bioactives

27-Mar-2015 - Evolva and Valent BioSciences Corporation (VBC), a subsidiary of Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are ...

Evolva and L’Oréal reach first milestone in cosmetics ingredient project

09-Jan-2015 - Evolva Holding SA announced the successful completion of the first part of its R&D collaboration with L’Oréal. The parties have agreed to move into the next phase of the multi-year programme. Under this collaboration, which started in February 2014, Evolva and L’Oréal are applying Evolva’s ...

Evolva to acquire Allylix

19-Nov-2014 - Evolva Holding SA has agreed to acquire San Diego-based Allylix, Inc., a privately held yeast fermentation company with a focus on high-value ingredients, in an all-stock transaction. The acquisition will immediately expand Evolva’s product and IP portfolio and enhance the competitiveness of ...

Malaysian Biotechnology Corporation, Universiti Malaysia Pahang and Evolva collaborate to establish centre of excellence for Malaysian Natural Products

Focus on Biosynthesis of High Value Indigenous Malaysian Natural Products

10-Jun-2014 - Evolva Holding SA announced that it will collaborate with Universiti Malaysia Pahang (UMP) to establish a scientific Centre of Excellence for natural products from Malaysia as part of the Flavor and Fragrance Cluster in the state of Pahang. The Centre of Excellence, which is being facilitated by ...